Methods and products obtained from the method for culturing stem cells and tissues using stem cells, cord tissue fragments, or stem cells, decellularized cord tissue fragments, or mixed cells from cord tissue or combinations thereof to amplify stem cells are described.

The invention belongs to the fields of cell biology and medicine, and relates to the medical use of NOTCH4 or the medical use of NOTCH4 inhibitors. In particular, the invention relates to use of NOTCH4 protein or NOTCH4 gene for manufacture of a medicament for promoting hematopoietic stem/progenitor cell differentiation and megakaryocyte differentiation in a mammal, a medicament for treating megakaryocyte dysplasia, or a medicament for promoting platelet production. The invention can effectively promote the production of hematopoietic stem/progenitor cells and megakaryocytes in vitro, thereby significantly improving the efficiency of platelet production in vitro, and having a good application prospect.

A method for preparing a liver or pancreas implant including the steps of: providing a carrier matrix suitable for tissue engineering and a cell suspension comprising viable hepatocytes and/or cells of islets of Langerhans in a standard culture medium A; loading the cell suspension onto the carrier matrix; incubating the loaded matrix for a first incubation time T1 of at least 10 hours at about 37 C. in either standard culture medium A or a culture medium B comprising standard culture medium A and 0.5% to 5% secretome; exchanging the culture medium of step 2c) with culture medium B comprising standard culture medium A and 0.5% to 5% secretome; incubating the loaded matrix for a second incubation time T2 of at least 24 hours at about 37 C. in culture medium B; washing the loaded matrix of step e) with standard culture medium A to remove at least part of the secretome.

Compositions and methods of use pertaining to exosomes, and more particularly to exosomes from pericytes and endothelial progenitor cells are presented.

Provided are a pharmaceutical composition for regenerating skin, a pharmaceutical composition for improving wrinkles, a pharmaceutical composition for treating wounds, a quasi-drug composition for regenerating skin, a quasi-drug composition for improving wrinkles, a quasi-drug composition for treating wounds, a cosmetic composition for regenerating skin, a cosmetic composition for improving wrinkles, a cosmetic composition for improving wounds, and a medium composition for culturing fibroblasts, each composition including GDF11 or a human-derived adult stem cell culture medium including the same, a method of culturing fibroblasts by using the medium composition, and a method of preparing GDF11 by culturing stem cells. The GDF11 provided in the present invention may be included in a human-derived adult stem cell culture medium to exhibit an effect of promoting fibroblast proliferation, and may thereby be widely applied to the development of a variety of products for skin regeneration, wrinkle improvement, or wound treatment.

Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.

The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiation an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell produced by using the medium composition into hepatocytes. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into hepatocytes.

A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.

A fetal stem cell-derived extracellular vesicle has immune tolerance properties. The extracellular vesicle containing a fetal stem cell-derived primal immunoglobulin contains various natural antibodies and complement proteins which can immediately respond to foreign infectious agents such as viruses, bacteria, pathogens, etc., and thus can effectively treat and prevent infectious diseases through an enhanced innate immune system. Methods are disclosed for preparing the fetal stem cell-derived extracellular vesicle.

Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1aCD5 or CD34+CD7+CD1aCD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.